Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study

BMC Nephrology

Table 2 Univariate logistic regression analysis for the prediction of high on-clopidogrel platelet reactivity (PRI VASP ≥61 %)

Variable	OR	CI (95 %)	p
Age (years)	0.98	0.96–1.00	0.15
Sex (male)	1.63	0.85–3.14	0.15
Diabetes mellitus	1.54	0.80–2.96	0.20
Body mass index (kg/m²)	1.08	1.01–1.15	0.02
Hypertension	1.94	0.72–5.26	0.19
Tobacco	1.18	0.63–2.22	0.61
Dyslipidemia	1.93	0.83–4.50	0.13
eGFR (mL/min/1.73 m²)	0.99	0.98–1.00	0.09
CRP (mg/dL)	0.99	0.97–1.00	0.09
Kidney transplantation	2.61	1.22–5.55	0.01
Calcineurin inhibitors use	3.15	1.41–7.02	0.005
Anti-metabolites use	1.94	0.87–4.31	0.11
Proton pump inhibitor use	1.15	0.58–2.29	0.69

Abbreviations: PRI platelet reactivity index, VASP vasodilator-stimulated phosphoprotein, OR odds ratio, CI confidence interval, eGFR estimated glomerular filtration rate, CRP C-reactive protein

ISSN: 1471-2369